The agreement grants Dr Reddy’s exclusivity in the US for the distribution and marketing of EpiCeram while Ceragenix will be responsible for the manufacturing and supply of the product. Under the agreement, Ceragenix will receive certain milestone payments over the agreement period. Upon commercialization of the product, Ceragenix will receive royalty payments based on net sales. Dr Reddy’s expects to launch EpiCeram within a year through a new salesforce targeting dermatologists.
Steven Porter, chairman and CEO of Ceragenix, said: “We are very pleased to be partnering with Dr Reddy’s to commercialize EpiCeram. We are very impressed with the team assembled by Dr Reddy’s and we look to forward bringing this product into the market together. As we’ve stated in the past, we believe that patients and physicians alike will find EpiCeram’s combination of efficacy and safety profile to be a welcome alternative in the treatment of atopic dermatitis.”
http://biz.yahoo.com/bw/071119/20071119005423.html?.v=1